34 citations
,
December 2015 in “Neuroscience & Biobehavioral Reviews” In this study, several compounds, including estrogen and Dutasteride, showed neuroprotective effects on dopaminergic neurons in an MPTP mouse model of Parkinson's disease.
182 citations
,
January 2000 in “Drug Development Research” This study found that ethosomal carriers enhanced dermal and transdermal drug delivery more effectively than classic liposomes, improving delivery to deep skin layers and showing potential for treating conditions like herpes labialis and diabetes.
August 2019 in “bioRxiv (Cold Spring Harbor Laboratory)” This study developed the CATNIP computational model, which uses biological and chemical information to successfully identify drug repurposing opportunities for various conditions, including Parkinson’s disease and Type 2 Diabetes.
8 citations
,
August 2020 in “PLOS Computational Biology” This study presents a computational approach, CATNIP, which repurposes drugs using only their biological and chemical information, predicting new uses like adrenergic uptake inhibitors for Parkinson's and vandetanib for Type 2 Diabetes.
14 citations
,
October 2006 in “Journal of The American Academy of Dermatology” This report highlights a case where a woman's use of the dopamine agonist pramipexole for Parkinson's disease was associated with hair loss, which improved after discontinuing the drug.